论文部分内容阅读
目的:分析孟鲁司特钠与布地奈德对毛细支气管炎患儿血清嗜酸粒细胞阳离子蛋白(ECP)、白细胞介素-8(IL-8)的影响,比较二者对毛细支气管炎的疗效。方法:选取我院确诊的毛细支气管炎患儿100例,随机分为A组(孟鲁司特钠口服)和B组(布地奈德雾化)各50例,监测孟鲁司特钠和布地奈德干预前后血清ECP、IL-8水平,并随访治疗后1年的复发情况。结果:A组ECP浓度从干预前(19.15±13.34)μg/L降至干预后(9.58±5.21)μg/L,B组ECP浓度从干预前(20.47±12.21)μg/L降至干预后(5.15±4.01)μg/L。干预前两组ECP比较差异无统计学意义(t=1.002,P>0.05);干预后A组ECP显著低于B组,两组比较差异有统计学意义(t=3.396,P<0.01)。干预后两组IL-8均明显下降,但组间比较差异无统计学意义(干预前t=1.479,干预后t=0.187,P均>0.05)。结论:A组治疗后患儿血清ECP下降更明显,复发率更少,说明孟鲁司特钠比布地奈德能更有效地治疗毛细支气管炎。
Objective: To analyze the influence of montelukast sodium and budesonide on serum eosinophil cationic protein (ECP) and interleukin-8 (IL-8) in children with bronchiolitis and to compare the effects of montelukast on the bronchiolitis Efficacy. Methods: A total of 100 children with bronchiolitis diagnosed in our hospital were randomly divided into group A (oral montelukast sodium) and group B (budesonide nebulization) 50 cases. Montelukast sodium and budesonide The levels of serum ECP and IL-8 before and after Ned intervention were compared, and the recurrence was observed at 1 year after follow-up treatment. Results: The concentration of ECP in group A decreased from 19.15 ± 13.34 μg / L to 9.58 ± 5.21 μg / L before intervention, while that in group B decreased from 20.47 ± 12.21 μg / L before intervention to 5.15 ± 4.01) μg / L. There was no significant difference in ECP between the two groups before intervention (t = 1.002, P> 0.05). ECP in group A was significantly lower than that in group B after intervention (t = 3.396, P <0.01). After intervention, IL-8 in both groups decreased significantly, but there was no significant difference between the two groups (t = 1.479 before intervention, t = 0.187 after intervention, both P> 0.05). Conclusion: The serum ECP decreased more obviously and the recurrence rate was less in group A than in group A, which indicated that montelukast sodium could treat bronchiolitis more effectively than budesonide.